| Budget Amount *help |
¥3,600,000 (Direct Cost: ¥3,600,000)
Fiscal Year 2006: ¥1,300,000 (Direct Cost: ¥1,300,000)
Fiscal Year 2005: ¥2,300,000 (Direct Cost: ¥2,300,000)
|
|---|
| Research Abstract |
[Background and Purpose]
Polypoidal choroidal vasculopathy (PCV) is characterized by branching choroidal vessels with polyp-like terminal aneurismal dilations. Clinically, the vascular abnormality appears to be in the inner choroid and is composed of 2 basic elements: a polypoidal vessel and a branching vascular network. Although PCV is known to have a predilection for Asian populations, the exact pathology of it remains unclear and there are no current treatment guidelines. In this study, we aimed to evaluate choroidal vasculature and find efficient treatments for patients with PCV.
[Results]
1. Features o: vessels in PCV
(1) Pulsatile blood flow
We reviewed our series of cases of PCV with pulsatile polypoidal vessels and evaluated the features of such vessels in PCV. it is a unique and important characteristic that has not been reported with any other chorio-retinal diseases. (Ophthalmology, 112:1436-41, 2005)
(2) Diversity in PCV
We investigated the clinical features of PCV, in terms of le
… More
sion size and disease duration, during earlier and later disease stages and found differences between the groups. The results suggest that there may be subgroups in PCV; these subgroups are based or different pathologies but manifest similar polypoidal structures. Long-term observation of small-short cases could resolve his uncertainty. Further studies incorporating pathologies and treatments are required. (submitted)
2. Effect of Injection of triamcinolone acetonide (TA) for exudative age related macular degeneration / PCV
We evaluated the effect of intravitreal / sub-Tenon TA with exudative age related macular degeneration (AMD)/ PCV. Intravitreal TA provided short-term improvement in visual acuity and fundus findings in exudative AMD without significant side effects such as intraocular pressure increase and endophthalmitis. (Ophthalmologica, 220:118-24, 2006)
Trans-Tenon's retrobulbar TA injection may be a potential option for treating PCV from the point of view of effectiveness, safety, and cost. (Graefe's Archive for Clinical and Experimental Ophthalmology, 243:837-9, 2005) Less
|
